PrognomiQ

PrognomiQ is a clinical-stage biotech company with a mission to transform early detection and treatment through its proprietary multi-omics platform. Founded in 2020 as a spinout from Seer Inc., the company leverages unprecedented scale in proteomic data generation, combined with other 'omics' layers, to unlock novel biological insights for diagnostic development. Its strategy is to translate these discoveries into commercial diagnostic tests, positioning it within the competitive early cancer detection landscape. The company is publicly traded, providing capital markets access to fund its ambitious R&D agenda.

A proprietary multi-omics discovery platform centered on generating deep, large-scale proteomic data, which is then integrated with genomic and metabolomic data through advanced bioinformatics to identify novel disease signatures for diagnostic test development.

PrognomiQ competes in the crowded MCED space against leaders like GRAIL (Illumina) and Guardant Health, which use cfDNA-based methods. Its key differentiation is a foundational focus on deep proteomics integrated with other omics layers, a approach less common among major competitors. Success requires demonstrating clear clinical utility advantages over established technologies.